 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk of myocardial [0m
[34minfarction?[0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"TIGECYCLINE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mTIGECYCLINE[0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mTIGECYCLINE[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mdrug_category_search[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"drug_category_search"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"category"[0m[32m: [0m[32m"antibiotics"[0m[32m,[0m
[32m    [0m[32m"sub_categories"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"tetracyclines"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mdrug_category_search[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: [0m
[31mThe drugs in category antibiotics with sub-categories tetracyclines include:[0m
[31mMINOCYCLINE, PYLERA, DORYX MPC, DORYX, DOXYCLYCLINE HYCLATE, VIBRAMYCIN CALCIUM, BWELL FIRST AID ANTIBIOTIC, TETRACYTE TOPICAL TETRACYCLINE HYDROCHLORIDE, BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, [0m
[31mAND TETRACYCLINE HYDROCHLORIDE, ARESTIN, BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE, ACTICLATE, ORACEA, AMZEEQ, ADENOSINUM TRIPHOSPHORICUM DINATRUM, L-ASPARAGINE [0m
[1;31m([0m[31mMONOHYDRATE[0m[1;31m)[0m[31m, L-PHENYLALANINE, QUERCETIN, ILEUM [0m[1;31m([0m[31mSUIS[0m[1;31m)[0m[31m, JEJUNUM [0m[1;31m([0m[31mSUIS[0m[1;31m)[0m[31m, STOMACH [0m[1;31m([0m[31mSUIS[0m[1;31m)[0m[31m, ASCORBICUM ACIDUM, CALCAREA CARBONICA, FERRUM IODATUM, TETRACYCLINE, EGG [0m[1;31m([0m[31mHEN WHOLE[0m[1;31m)[0m[31m, PROTEUS [0m[1;31m([0m[31mMORGANI[0m[1;31m)[0m[31m, [0m
[31mDOXYCYCLATE HYCLATE, ERAVACYCLINE, SARECYCLINE HYDROCHLORIDE, DOXYCYCLINE, XERAVA, VIBRAMYCIN MONOHYDRATE, EGG ALLERGEN MIX, ZILXI, DOXY [0m[1;31m100[0m[1;31m([0m[31mTM[0m[1;31m)[0m[31m DOXYCYCLINE, SOLODYN, VIABECLINE FIRST AID ANTIBIOTIC, [0m
[31mDOXY [0m[1;31m100[0m[31m, DOXYCYCLINE MONOHYDRATE, MEASTEM FIRST AID AND ANTIBIOTIC, DOXYCYCLINE CALCIUM, TYGACIL, APT T3X TETRACYCLINE HYDROCHLORIDE FIRST AID ANTIBIOTIC, TETRACYCLINE HYDROCHLORIDE, BISMUTH [0m
[31mSUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, LYMEPAK, ANISTEM, MINOCIN, TIGECYCLINE, VIBRAMYCIN HYCLATE, TARGADOX, DEMECLOCYCLINE, DEMECLOCYCLINE HYDROCHLORIDE, DOXYCYCLINE [0m
[31mHYCLATE, OMADACYCLINE, DOXYCYCLINE HYCLATE DELAYED RELEASE, SEYSARA, VIABECLINE, ADENOSINUM TRIPHOSPHORICUM DINATRUM, L-ASPARAGINE [0m[1;31m([0m[31mMONOHYDRATE[0m[1;31m)[0m[31m, PHENYLALANINE, QUERCETIN, ILEUM [0m[1;31m([0m[31mSUIS[0m[1;31m)[0m[31m, JEJUNUM [0m
[1;31m([0m[31mSUIS[0m[1;31m)[0m[31m, STOMACH [0m[1;31m([0m[31mSUIS[0m[1;31m)[0m[31m, CANARY FEATHERS, CATTLE EPITHELIA, CHICKEN FEATHERS, DOG EPITHELIA, DUCK FEATHERS, GERBIL EPITHELIA, GOAT EPITHELIA, GOOSE FEATHERS, GUINEA PIG EPITHELIA, HAMSTER EPITHELIA, [0m
[31mHOG EPITHELIA, HORSE EPITHELIA, MOUSE EPITHELIA, PARAKEET FEATHERS, RABBIT EPITHELIA, RAT EPITHELIA, STANDARDIZED CAT HAIR, ASCORBICUM ACIDUM, CALCAREA CARBONICA, FERRUM IODATUM, TETRACYCLINE, EGG, [0m
[31mTETRACYTE TOPICAL, MINOCYCLINE HYDROCHLORIDE, NUZYRA, ACTICLATE CAP, VITASTEM, TETRACYTE TOPICAL - TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE [0m[1;31m3[0m[31m PERCENT A FIRST AID ANTIBIOTIC, and VITASTEM-TETRACYCLINE [0m
[31mHYDROCHLORIDE.[0m

[31mSOUR[0m[1;31mCE:c[0m[31montext[0m


[31mCONTENT: ACTICLATE CAP: clinical_pharmacology: - - - - - Tetracycline â‰¤[0m[1;31m4[0m[31m - - - - - - - - Haemophilus influenzae Tetracycline â‰¤[0m[1;31m2[0m[31m [0m[1;31m4[0m[31m â‰¥[0m[1;31m8[0m[31m â‰¥[0m[1;31m29[0m[31m [0m[1;31m26[0m[31m-[0m[1;31m28[0m[31m â‰¤[0m[1;31m25[0m[31m - - - Mycoplasma pneumoniae b Tetracycline - - - - - [0m
[31mâ‰¤[0m[1;31m2[0m[31m - - Nocardiae and other aerobic Actinomyces species b Doxycycline â‰¤[0m[1;31m1[0m[31m [0m[1;31m2[0m[31m-[0m[1;31m4[0m[31m â‰¥[0m[1;31m8[0m[31m - - - - - Neisseria gonorrhoeae species c Tetracycline - - - â‰¥[0m[1;31m38[0m[31m [0m[1;31m31[0m[31m-[0m[1;31m37[0m[31m â‰¤[0m[1;31m30[0m[31m â‰¤[0m[1;31m0.25[0m[31m [0m[1;31m0.5[0m[31m-[0m[1;31m1[0m[31m â‰¥[0m[1;31m2[0m[31m Streptococcus pneumoniae [0m
[31mDoxycycline â‰¤[0m[1;31m0.25[0m[31m [0m[1;31m0[0m[31m. ACTICLATE CAP: clinical_pharmacology: [0m[1;31m5[0m[31m â‰¥[0m[1;31m1[0m[31m â‰¥[0m[1;31m28[0m[31m [0m[1;31m25[0m[31m-[0m[1;31m27[0m[31m â‰¤[0m[1;31m24[0m[31m - - - Tetracycline â‰¤[0m[1;31m1[0m[31m [0m[1;31m2[0m[31m â‰¥[0m[1;31m4[0m[31m â‰¥[0m[1;31m28[0m[31m [0m[1;31m25[0m[31m-[0m[1;31m27[0m[31m â‰¤[0m[1;31m24[0m[31m - - - Vibrio cholerae Doxycycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Tetracycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - [0m
[31m- - - - Yersinia pestis Doxycycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Tetracycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Ureaplasma urealyticum Tetracycline - - - - - - â‰¤[0m[1;31m1[0m[31m - â‰¥[0m[1;31m2[0m[31m Doxycycline susceptibility testing interpretive [0m
[31mcriteria for anaerobes, Haemophilus influenzae, Mycoplasma pneumoniae, Neisseria gonorrhoeae , and Ureaplasma urealyticum have not been established. ACTICLATE CAP: clinical_pharmacology: Isolates of [0m
[31mthese species that are susceptible to tetracycline are also considered susceptible to doxycycline. [0m[1;31m5[0m[31m A report of Susceptible [0m[1;31m([0m[31mS[0m[1;31m)[0m[31m indicates that the antimicrobial drug is likely to inhibit growth of [0m
[31mthe pathogen if the antimicrobial drug reaches the concentration usually achievable at the site of infection. A report of Intermediate [0m[1;31m([0m[31mI[0m[1;31m)[0m[31m indicates that the result should be considered equivocal, [0m
[31mand, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the[0m
[31mdrug product is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from [0m
[31mcausing major discrepancies in interpretation. ACTICLATE CAP: clinical_pharmacology: A report of Resistant [0m[1;31m([0m[31mR[0m[1;31m)[0m[31m indicates that the antimicrobial drug is not likely to inhibit growth of the pathogen if [0m
[31mthe antimicrobial drug reaches the concentration usually achievable at the infection site; other therapy should be selected. Quality Control Standardized susceptibility test procedures require the use[0m
[31mof laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test [0m[1;31m5[0m[31m,[0m[1;31m6[0m[31m,[0m[1;31m7[0m[31m,[0m[1;31m8[0m[31m,[0m[1;31m9[0m[31m,[0m[1;31m10[0m[31m,[0m[1;31m11[0m[31m . [0m
[31mStandard doxycycline powders should provide the following range of MIC values noted in Table [0m[1;31m2[0m[31m . For the diffusion technique using the [0m[1;31m30[0m[31m mcg doxycycline disk, the criteria noted in Table [0m[1;31m2[0m[31m should be [0m
[31machieved. ACTICLATE CAP: clinical_pharmacology: Table [0m[1;31m2[0m[31m: Acceptable Quality Control Ranges for Doxycycline and Tetracycline a ATCC is the American Type Culture Collection QC Strain Minimal Inhibitory [0m
[31mConcentration [0m[1;31m([0m[31mmcg per mL[0m[1;31m)[0m[31m Disk Diffusion [0m[1;31m([0m[31mzone diameter mm[0m[1;31m)[0m[31m Agar Dilution [0m[1;31m([0m[31mmcg/ml[0m[1;31m)[0m[31m Enterococcus faecalis ATCC a [0m[1;31m29212[0m[31m Doxycycline [0m[1;31m2[0m[31m â€“ [0m[1;31m8[0m[31m - - Tetracycline [0m[1;31m8[0m[31m-[0m[1;31m32[0m[31m - - Escherichia coli ATCC [0m[1;31m25922[0m[31m [0m
[31mDoxycycline [0m[1;31m0.5[0m[31m â€“ [0m[1;31m2[0m[31m [0m[1;31m18[0m[31m â€“ [0m[1;31m24[0m[31m - Tetracycline [0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:AC[0m[31mTICLATE CAP label[0m


[31mCONTENT: DEMECLOCYCLINE HYDROCHLORIDE: precautions: Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with [0m
[31mantibiotics, patients can develop watery and bloody stools [0m[1;31m([0m[31mwith or without stomach cramps and fever[0m[1;31m)[0m[31m even as late as two or more months after having taken the last dose of the antibiotic. If this [0m
[31moccurs, patients should contact their physician as soon as possible. Laboratory Tests In venereal diseases when coexistent syphilis is suspected, darkfield examination should be done before treatment [0m
[31mis started and the blood serology repeated monthly for at least [0m[1;31m4[0m[31m months. In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal and hepatic, should be [0m
[31mperformed. All patients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with demeclocycline HCl should have a follow-up serologic test for syphilis [0m
[31mafter [0m[1;31m3[0m[31m months. DEMECLOCYCLINE HYDROCHLORIDE: precautions: Drug Interactions Because tetracyclines have shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may [0m
[31mrequire downward adjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillins, it is advisable to avoid giving tetracycline-class [0m
[31mdrugs in conjunction with penicillin. Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. The concurrent use of tetracyclines and methoxyflurane has[0m
[31mbeen reported to result in fatal renal toxicity. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and by iron-containing preparations. Carcinogenesis, [0m
[31mMutagenesis, Impairment of Fertility Long-term studies in animals to evaluate carcinogenic potential of demeclocycline HCl have not been conducted. DEMECLOCYCLINE HYDROCHLORIDE: precautions: However, [0m
[31mthere has been evidence of oncogenic activity in rats in studies with the related antibiotics oxytetracycline [0m[1;31m([0m[31madrenal and pituitary tumors[0m[1;31m)[0m[31m and minocycline [0m[1;31m([0m[31mthyroid tumors[0m[1;31m)[0m[31m. Although mutagenicity [0m
[31mstudies of demeclocycline HCl have not been conducted, positive results in in vitro mammalian cell assays [0m[1;31m([0m[31mi.e., mouse lymphoma and Chinese hamster lung cells[0m[1;31m)[0m[31m have been reported for related [0m
[31mantibiotics [0m[1;31m([0m[31mtetracyclines HCl and oxytetracycline[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS and ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY [0m[1;31m)[0m[31m. Demeclocycline HCl had no effect on fertility when administered in the diet to male [0m
[31mand female rats at a daily intake of [0m[1;31m45[0m[31m times the human dose. Pregnancy Teratogenic effects Pregnancy Category D [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m. DEMECLOCYCLINE HYDROCHLORIDE: precautions: Result of animal studies [0m
[31mindicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus [0m[1;31m([0m[31moften related to retardation of skeletal development[0m[1;31m)[0m[31m. Evidence of [0m
[31membryotoxicity has been noted in animals treated early in pregnancy. Nonteratogenic effects [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m Labor and Delivery The effect of tetracyclines on labor and delivery is unknown. Nursing [0m
[31mMothers Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue [0m
[31mnursing or discontinue the drug, taking into account the importance of the drug to the mother [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Pediatric Use Not for use in patients younger than eight years of age [0m[31m.         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mMECLOCYCLINE HYDROCHLORIDE label[0m


[31mCONTENT: MINOCIN: drug_interactions: Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward [0m
[31madjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction [0m
[31mwith penicillin. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations. The concurrent use of tetracycline and methoxyflurane[0m
[31mhas been reported to result in fatal renal toxicity. Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. Administration of isotretinoin should be [0m
[31mavoided shortly before, during, and shortly after minocycline therapy. Each drug alone has been associated with pseudotumor cerebri. [0m[1;31m([0m[31mSee PRECAUTIONS . MINOCIN: drug_interactions: [0m[1;31m)[0m[31m Increased risk of [0m
[31mergotism when ergot alkaloids or their derivatives are given with tetracyclines.         [0m
[31mSOURCE:MINOCIN label[0m


[31mCONTENT: DOXY [0m[1;31m100[0m[1;31m([0m[31mTM[0m[1;31m)[0m[31m DOXYCYCLINE: description: DESCRIPTION Doxycycline hyclate is soluble in water and chars at [0m[1;31m201[0m[31mÂ°C without melting. The base doxycycline has a high degree of lipid solubility and a[0m
[31mlow affinity for calcium binding. It is highly stable in normal human serum. Each [0m[1;31m100[0m[31m mg vial contains: Doxycycline hyclate equivalent to [0m[1;31m100[0m[31m mg doxycycline; ascorbic acid [0m[1;31m480[0m[31m mg; mannitol [0m[1;31m300[0m[31m mg. pH [0m
[31mof the reconstituted solution [0m[1;31m([0m[1;31m10[0m[31m mg/mL[0m[1;31m)[0m[31m is between [0m[1;31m1.8[0m[31m and [0m[1;31m3.3[0m[31m. Doxycycline for Injection, USP is a sterile, lyophilized powder prepared from a solution of doxycycline hyclate, ascorbic acid and [0m
[31mmannitol in Water for Injection. Doxycycline hyclate is a broad spectrum antibiotic derived from oxytetracycline. DOXY [0m[1;31m100[0m[1;31m([0m[31mTM[0m[1;31m)[0m[31m DOXYCYCLINE: description: It is meant for INTRAVENOUS use only after [0m
[31mreconstitution. Doxycycline hyclate is a yellowish crystalline powder which is chemically designated [0m[1;31m4[0m[31m-[0m[1;31m([0m[31mDimethylamino[0m[1;31m)[0m[1;31m-1[0m[31m,[0m[1;31m4[0m[31m,4a,[0m[1;31m5[0m[31m,5a,[0m[1;31m6[0m[31m,[0m[1;31m11[0m[31m, 12a-octahydro-[0m[1;31m3[0m[31m,[0m[1;31m5[0m[31m,[0m[1;31m10[0m[31m,[0m[1;31m12[0m[31m,12a-pentahydroxy-[0m[1;31m6[0m[31m-methyl-[0m[1;31m1[0m[31m,[0m[1;31m11[0m[31m-de [0m
[31mmonohydrochloride, compound with ethyl alcohol [0m[1;31m([0m[1;31m2:1[0m[1;31m)[0m[31m, monohydrate. It has the following structural formula: Doxycycline hyclate is soluble in water and chars at [0m[1;31m201[0m[31mÂ°C without melting. The base [0m
[31mdoxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. DOXY [0m[1;31m100[0m[1;31m([0m[31mTM[0m[1;31m)[0m[31m DOXYCYCLINE: description: Each [0m[1;31m100[0m[31m mg vial contains: [0m
[31mDoxycycline hyclate equivalent to [0m[1;31m100[0m[31m mg doxycycline; ascorbic acid [0m[1;31m480[0m[31m mg; mannitol [0m[1;31m300[0m[31m mg. pH of the reconstituted solution [0m[1;31m([0m[1;31m10[0m[31m mg/mL[0m[1;31m)[0m[31m is between [0m[1;31m1.8[0m[31m and [0m[1;31m3.3[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXY [0m[1;31m100[0m[1;31m([0m[31mTM[0m[1;31m)[0m[31m DOXYCYCLINE label[0m


[31mCONTENT: DOXY [0m[1;31m100[0m[31m: description: DESCRIPTION Doxycycline hyclate is soluble in water and chars at [0m[1;31m201[0m[31mÂ°C without melting. The base doxycycline has a high degree of lipid solubility and a low affinity [0m
[31mfor calcium binding. It is highly stable in normal human serum. Each [0m[1;31m100[0m[31m mg vial contains: Doxycycline hyclate equivalent to [0m[1;31m100[0m[31m mg doxycycline; ascorbic acid [0m[1;31m480[0m[31m mg; mannitol [0m[1;31m300[0m[31m mg. pH of the [0m
[31mreconstituted solution [0m[1;31m([0m[1;31m10[0m[31m mg/mL[0m[1;31m)[0m[31m is between [0m[1;31m1.8[0m[31m and [0m[1;31m3.3[0m[31m. Doxycycline for Injection, USP is a sterile, lyophilized powder prepared from a solution of doxycycline hyclate, ascorbic acid and mannitol in[0m
[31mWater for Injection. Doxycycline hyclate is a broad spectrum antibiotic derived from oxytetracycline. DOXY [0m[1;31m100[0m[31m: description: It is meant for INTRAVENOUS use only after reconstitution. Doxycycline [0m
[31mhyclate is a yellowish crystalline powder which is chemically designated [0m[1;31m4[0m[31m-[0m[1;31m([0m[31mDimethylamino[0m[1;31m)[0m[1;31m-1[0m[31m,[0m[1;31m4[0m[31m,4a,[0m[1;31m5[0m[31m,5a,[0m[1;31m6[0m[31m,[0m[1;31m11[0m[31m, 12a-octahydro-[0m[1;31m3[0m[31m,[0m[1;31m5[0m[31m,[0m[1;31m10[0m[31m,[0m[1;31m12[0m[31m,12a-pentahydroxy-[0m[1;31m6[0m[31m-methyl-[0m[1;31m1[0m[31m,[0m[1;31m11[0m[31m-de monohydrochloride, compound with [0m
[31methyl alcohol [0m[1;31m([0m[1;31m2:1[0m[1;31m)[0m[31m, monohydrate. It has the following structural formula: Doxycycline hyclate is soluble in water and chars at [0m[1;31m201[0m[31mÂ°C without melting. The base doxycycline has a high degree of lipid [0m
[31msolubility and a low affinity for calcium binding. It is highly stable in normal human serum. DOXY [0m[1;31m100[0m[31m: description: Each [0m[1;31m100[0m[31m mg vial contains: Doxycycline hyclate equivalent to [0m[1;31m100[0m[31m mg doxycycline; [0m
[31mascorbic acid [0m[1;31m480[0m[31m mg; mannitol [0m[1;31m300[0m[31m mg. pH of the reconstituted solution [0m[1;31m([0m[1;31m10[0m[31m mg/mL[0m[1;31m)[0m[31m is between [0m[1;31m1.8[0m[31m and [0m[1;31m3.3[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXY [0m[1;31m100[0m[31m label[0m


[31mCONTENT: BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: [0m[1;31m14[0m[31m , [0m[1;31m7.5[0m[31m [0m[1;31m)[0m[31m Lithium: Increased lithium serum concentrations; measure serum lithium and serum [0m
[31mcreatinine concentrations during therapy. [0m[1;31m([0m[31m [0m[1;31m5.14[0m[31m , [0m[1;31m7.6[0m[31m [0m[1;31m)[0m[31m Antacids, Multivitamins or Dairy Products: Decreased absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride [0m
[31mcapsules; do not take concomitantly. [0m[1;31m([0m[31m [0m[1;31m7.7[0m[31m [0m[1;31m)[0m[31m Busulfan: Increased busulfan serum concentrations; avoid concomitant use, monitor for busulfan toxicity. [0m[1;31m([0m[31m [0m[1;31m7.8[0m[31m [0m[1;31m)[0m[31m CYP inducers and CYP inhibitors: Prolonged[0m
[31mor accelerated half-life of metronidazole or concomitant medications; use with caution. [0m[1;31m([0m[31m [0m[1;31m7.9[0m[31m , [0m[1;31m7.10[0m[31m [0m[1;31m)[0m[31m [0m[1;31m7[0m[31m. BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: [0m[1;31m1[0m[31m [0m
[31mMethoxyflurane Do not administer methoxyflurane to patients taking bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules. The concurrent use of tetracycline [0m
[31mhydrochloride, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules, with methoxyflurane has been reported to result in fatal renal toxicity [0m[1;31m[[0m[31m see [0m
[31mContraindications [0m[1;31m([0m[31m [0m[1;31m4.1[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m . [0m[1;31m7.2[0m[31m Disulfiram Psychotic reactions have been reported in alcoholic patients who are using metronidazole, a component of bismuth subcitrate potassium, metronidazole and [0m
[31mtetracycline hydrochloride capsules and disulfiram concurrently. BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: Bismuth subcitrate potassium, metronidazole[0m
[31mand tetracycline hydrochloride capsules should not be given to patients who have taken disulfiram within the last two weeks [0m[1;31m[[0m[31m see Contraindications [0m[1;31m([0m[31m [0m[1;31m4.2[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m . [0m[1;31m7.3[0m[31m Alcohol Consumption of alcoholic [0m
[31mbeverages or administration of other products containing propylene glycol during treatment with bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and for at least [0m[1;31m3[0m[31m [0m
[31mdays afterwards may cause a disulfiram-like reaction [0m[1;31m([0m[31mabdominal cramps, nausea, vomiting, headaches, and flushing[0m[1;31m)[0m[31m due to the interaction between alcohol or propylene glycol and metronidazole, a [0m
[31mcomponent of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules. BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: [0m
[31mDiscontinue alcoholic beverage or other products containing propylene glycol during and for at least [0m[1;31m3[0m[31m days after therapy with bismuth subcitrate potassium, metronidazole and tetracycline [0m
[31mhydrochloride capsules [0m[1;31m[[0m[31m see Contraindications [0m[1;31m([0m[31m [0m[1;31m4.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m . [0m[1;31m7.4[0m[31m Oral Contraceptives Concurrent use of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules with oral [0m
[31mcontraceptive may make oral contraceptives less effective due to an interaction with the tetracycline component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules. [0m
[31mBreakthrough bleeding has been reported. Women of child-bearing potential should use a different or additional form of contraception while taking bismuth subcitrate potassium, metronidazole and [0m
[31mtetracycline hydrochloride capsules [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.14[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m . [0m[1;31m7[0m[31m. BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: [0m[1;31m5[0m[31m Anticoagulants Bismuth [0m
[31msubcitrate potassium, metronidazole and tetracycline hydrochloride capsules may alter the anticoagulant effects of warfarin and other oral coumarin anticoagulants. Metronidazole has been reported to [0m
[31mpotentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. Tetracycline has been shown to depress plasma prothrombin [0m
[31mactivity. Prothrombin time, International Normalized Ratio [0m[1;31m([0m[31mINR[0m[1;31m)[0m[31m, or other suitable anticoagulation tests should be closely monitored if bismuth subcitrate potassium, metronidazole and tetracycline [0m
[31mhydrochloride capsules are administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.14[0m[31m [0m[1;31m)[0m[31m [0m[1;31m][0m[31m . [0m[1;31m7[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:B[0m[31mISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE label[0m


[31mCONTENT: DEMECLOCYCLINE: precautions: Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, [0m
[31mpatients can develop watery and bloody stools [0m[1;31m([0m[31mwith or without stomach cramps and fever[0m[1;31m)[0m[31m even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients[0m
[31mshould contact their physician as soon as possible. Laboratory Tests In venereal diseases when coexistent syphilis is suspected, darkfield examination should be done before treatment is started and [0m
[31mthe blood serology repeated monthly for at least [0m[1;31m4[0m[31m months. In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal and hepatic, should be performed. All [0m
[31mpatients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with demeclocycline HCl should have a follow-up serologic test for syphilis after [0m[1;31m3[0m[31m months.[0m
[31mDEMECLOCYCLINE: precautions: Drug Interactions Because tetracyclines have shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of [0m
[31mtheir anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillins, it is advisable to avoid giving tetracycline-class drugs in conjunction with [0m
[31mpenicillin. Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. The concurrent use of tetracyclines and methoxyflurane has been reported to result [0m
[31min fatal renal toxicity. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and by iron-containing preparations. Carcinogenesis, Mutagenesis, Impairment of [0m
[31mFertility Long-term studies in animals to evaluate carcinogenic potential of demeclocycline HCl have not been conducted. DEMECLOCYCLINE: precautions: However, there has been evidence of oncogenic [0m
[31mactivity in rats in studies with the related antibiotics oxytetracycline [0m[1;31m([0m[31madrenal and pituitary tumors[0m[1;31m)[0m[31m and minocycline [0m[1;31m([0m[31mthyroid tumors[0m[1;31m)[0m[31m. Although mutagenicity studies of demeclocycline HCl have not [0m
[31mbeen conducted, positive results in in vitro mammalian cell assays [0m[1;31m([0m[31mi.e., mouse lymphoma and Chinese hamster lung cells[0m[1;31m)[0m[31m have been reported for related antibiotics [0m[1;31m([0m[31mtetracyclines HCl and [0m
[31moxytetracycline[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS and ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY [0m[1;31m)[0m[31m. Demeclocycline HCl had no effect on fertility when administered in the diet to male and female rats at a daily intake of[0m
[1;31m45[0m[31m times the human dose. Pregnancy Teratogenic effects Pregnancy Category D [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m. DEMECLOCYCLINE: precautions: Result of animal studies indicate that tetracyclines cross the placenta, are [0m
[31mfound in fetal tissues, and can have toxic effects on the developing fetus [0m[1;31m([0m[31moften related to retardation of skeletal development[0m[1;31m)[0m[31m. Evidence of embryotoxicity has been noted in animals treated early in[0m
[31mpregnancy. Nonteratogenic effects [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m Labor and Delivery The effect of tetracyclines on labor and delivery is unknown. Nursing Mothers Tetracyclines are excreted in human milk. Because of [0m
[31mthe potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the [0m
[31mimportance of the drug to the mother [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Pediatric Use Not for use in patients younger than eight years of age [0m[31m.         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mMECLOCYCLINE label[0m


[31mCONTENT: ACTICLATE: clinical_pharmacology: - - - - - Tetracycline â‰¤[0m[1;31m4[0m[31m - - - - - - - - Haemophilus influenzae Tetracycline â‰¤[0m[1;31m2[0m[31m [0m[1;31m4[0m[31m â‰¥[0m[1;31m8[0m[31m â‰¥[0m[1;31m29[0m[31m [0m[1;31m26[0m[31m-[0m[1;31m28[0m[31m â‰¤[0m[1;31m25[0m[31m - - - Mycoplasma pneumoniae b Tetracycline - - - - - â‰¤[0m[1;31m2[0m[31m -[0m
[31m- Nocardiae and other aerobic Actinomyces species b Doxycycline â‰¤[0m[1;31m1[0m[31m [0m[1;31m2[0m[31m-[0m[1;31m4[0m[31m â‰¥[0m[1;31m8[0m[31m - - - - - Neisseria gonorrhoeae species c Tetracycline - - - â‰¥[0m[1;31m38[0m[31m [0m[1;31m31[0m[31m-[0m[1;31m37[0m[31m â‰¤[0m[1;31m30[0m[31m â‰¤[0m[1;31m0.25[0m[31m [0m[1;31m0.5[0m[31m-[0m[1;31m1[0m[31m â‰¥[0m[1;31m2[0m[31m Streptococcus pneumoniae Doxycycline[0m
[31mâ‰¤[0m[1;31m0.25[0m[31m [0m[1;31m0[0m[31m. ACTICLATE: clinical_pharmacology: [0m[1;31m5[0m[31m â‰¥[0m[1;31m1[0m[31m â‰¥[0m[1;31m28[0m[31m [0m[1;31m25[0m[31m-[0m[1;31m27[0m[31m â‰¤[0m[1;31m24[0m[31m - - - Tetracycline â‰¤[0m[1;31m1[0m[31m [0m[1;31m2[0m[31m â‰¥[0m[1;31m4[0m[31m â‰¥[0m[1;31m28[0m[31m [0m[1;31m25[0m[31m-[0m[1;31m27[0m[31m â‰¤[0m[1;31m24[0m[31m - - - Vibrio cholerae Doxycycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Tetracycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Yersinia[0m
[31mpestis Doxycycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Tetracycline â‰¤[0m[1;31m4[0m[31m [0m[1;31m8[0m[31m â‰¥[0m[1;31m16[0m[31m - - - - - - Ureaplasma urealyticum Tetracycline - - - - - - â‰¤[0m[1;31m1[0m[31m - â‰¥[0m[1;31m2[0m[31m Doxycycline susceptibility testing interpretive criteria for [0m
[31manaerobes, Haemophilus influenzae, Mycoplasma pneumoniae, Neisseria gonorrhoeae , and Ureaplasma urealyticum have not been established. ACTICLATE: clinical_pharmacology: Isolates of these species that[0m
[31mare susceptible to tetracycline are also considered susceptible to doxycycline. [0m[1;31m5[0m[31m A report of Susceptible [0m[1;31m([0m[31mS[0m[1;31m)[0m[31m indicates that the antimicrobial drug is likely to inhibit growth of the pathogen if the [0m
[31mantimicrobial drug reaches the concentration usually achievable at the site of infection. A report of Intermediate [0m[1;31m([0m[31mI[0m[1;31m)[0m[31m indicates that the result should be considered equivocal, and, if the [0m
[31mmicroorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug [0m
[31mproduct is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from [0m
[31mcausing major discrepancies in interpretation. ACTICLATE: clinical_pharmacology: A report of Resistant [0m[1;31m([0m[31mR[0m[1;31m)[0m[31m indicates that the antimicrobial drug is not likely to inhibit growth of the pathogen if the [0m
[31mantimicrobial drug reaches the concentration usually achievable at the infection site; other therapy should be selected. Quality Control Standardized susceptibility test procedures require the use of [0m
[31mlaboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test [0m[1;31m5[0m[31m,[0m[1;31m6[0m[31m,[0m[1;31m7[0m[31m,[0m[1;31m8[0m[31m,[0m[1;31m9[0m[31m,[0m[1;31m10[0m[31m,[0m[1;31m11[0m[31m . [0m
[31mStandard doxycycline powders should provide the following range of MIC values noted in Table [0m[1;31m2[0m[31m . For the diffusion technique using the [0m[1;31m30[0m[31m mcg doxycycline disk, the criteria noted in Table [0m[1;31m2[0m[31m should be [0m
[31machieved. ACTICLATE: clinical_pharmacology: Table [0m[1;31m2[0m[31m: Acceptable Quality Control Ranges for Doxycycline and Tetracycline a ATCC is the American Type Culture Collection QC Strain Minimal Inhibitory [0m
[31mConcentration [0m[1;31m([0m[31mmcg per mL[0m[1;31m)[0m[31m Disk Diffusion [0m[1;31m([0m[31mzone diameter mm[0m[1;31m)[0m[31m Agar Dilution [0m[1;31m([0m[31mmcg/ml[0m[1;31m)[0m[31m Enterococcus faecalis ATCC a [0m[1;31m29212[0m[31m Doxycycline [0m[1;31m2[0m[31m â€“ [0m[1;31m8[0m[31m - - Tetracycline [0m[1;31m8[0m[31m-[0m[1;31m32[0m[31m - - Escherichia coli ATCC [0m[1;31m25922[0m[31m [0m
[31mDoxycycline [0m[1;31m0.5[0m[31m â€“ [0m[1;31m2[0m[31m [0m[1;31m18[0m[31m â€“ [0m[1;31m24[0m[31m - Tetracycline [0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:AC[0m[31mTICLATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: TIGECYCLINE is included in the list of drugs that belong to the category of antibiotics, specifically under the sub-category of tetracyclines.[0m

[32mSOURCE: context[0m
[32mEXTRACT_START_END: The drugs in category antibiotics[0m[32m...[0m[32m TIGECYCLINE, VIBRAMYCIN HYCLATE, [0m[32m...[0m
*[1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: TIGECYCLINE is included in the list of drugs that belong[0m
[34mto the category of antibiotics, specifically under the sub-category of tetracyclines.[0m

[34mSOURCE: context[0m
[34mEXTRACT_START_END: The drugs in category antibiotics[0m[34m...[0m[34m TIGECYCLINE, VIBRAMYCIN HYCLATE, [0m[34m...[0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does the FDA label for TIGECYCLINE mention an increased or decreased risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes the FDA label for TIGECYCLINE mention an increased or [0m
[32mdecreased risk of myocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes the FDA label for TIGECYCLINE mention an increased or decreased risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does the FDA label for TIGECYCLINE mention an increased or decreased risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"tigecycline"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: TIGECYCLINE: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: All-Cause Mortality [0m[31m Mortality Imbalance and Lower Cure [0m
[31mRates in Hospital-Acquired Pneumonia [0m[31m Anaphylaxis [0m[1;31m[[0m[31mWarning and Precautions [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Hepatic Adverse Effects [0m[1;31m[[0m[31mWarnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Pancreatitis [0m[1;31m[[0m[31mWarnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[1;31m][0m[31m The most [0m
[31mcommon adverse reactions [0m[1;31m([0m[31mincidence >[0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m are nausea, vomiting, diarrhea, abdominal pain, headache, and increased SGPT. [0m[1;31m([0m[31m [0m[1;31m6.1[0m[31m [0m[1;31m)[0m[31m To report SUSPECTED ADVERSE REACTIONS, contact Apotex at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m706[0m[31m-[0m[1;31m5575[0m[31m [0m
[31mor FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www. TIGECYCLINE: adverse_reactions: da.gov/medwatch [0m[1;31m6.1[0m[31m Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction [0m
[31mrates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, [0m[1;31m2514[0m
[31mpatients were treated with tigecycline for injection. Tigecycline for injection was discontinued due to adverse reactions in [0m[1;31m7[0m[31m% of patients compared to [0m[1;31m6[0m[31m% for all comparators. Table [0m[1;31m1[0m[31m shows the [0m
[31mincidence of adverse reactions through test of cure reported in â‰¥[0m[1;31m2[0m[31m% of patients in these trials. Table [0m[1;31m1[0m[31m. TIGECYCLINE: adverse_reactions: Incidence [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m of Adverse Reactions Through Test of Cure [0m
[31mReported in â‰¥ [0m[1;31m2[0m[31m% of Patients Treated in Clinical Studies Body System Tigecycline for injection Comparators a Adverse Reactions [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m2514[0m[1;31m)[0m[31m [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m2307[0m[1;31m)[0m[31m a Vancomycin/Aztreonam, Imipenem/Cilastatin, [0m
[31mLevofloxacin, Linezolid. b LFT abnormalities in tigecycline for injection-treated patients were reported more frequently in the post therapy period than those in comparator-treated patients, which [0m
[31moccurred more often on therapy.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: recent_major_changes: RECENT MAJOR CHANGES SECTION Dosage and Administration, Monitoring of Blood Coagulation Parameters [0m[1;31m([0m[1;31m2.4[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m/[0m[1;31m2020[0m[31m Warnings and Precautions, Monitoring of [0m
[31mBlood Coagulation Parameters [0m[1;31m([0m[1;31m5.6[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m/[0m[1;31m2020[0m[31m Warnings and Precautions, Tooth Discoloration and Enamel Hypoplasia [0m[1;31m([0m[1;31m5.7[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m/[0m[1;31m2020[0m[31m Warnings and Precautions, Inhibition of Bone Growth [0m[1;31m([0m[1;31m5[0m[31m. TIGECYCLINE: [0m
[31mrecent_major_changes: [0m[1;31m8[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m/[0m[1;31m2020[0m[31m         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: METOPROLOL TARTRATE: clinical_pharmacology: CLINICAL PHARMACOLOGY Mechanism of Action Metoprolol tartrate is a beta [0m[1;31m1[0m[31m -selective [0m[1;31m([0m[31mcardioselective[0m[1;31m)[0m[31m adrenergic receptor blocker. This [0m
[31mpreferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta [0m[1;31m2[0m[31m -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Clinical[0m
[31mpharmacology studies have demonstrated the beta-blocking activity of metoprolol, as shown by [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in heart rate and cardiac output at rest and upon exercise, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic blood [0m
[31mpressure upon exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol-induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m reduction of reflex orthostatic tachycardia. Hypertension The mechanism of the antihypertensive effects of [0m
[31mbeta-blocking agents has not been fully elucidated. METOPROLOL TARTRATE: clinical_pharmacology: However, several possible mechanisms have been proposed: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at[0m
[31mperipheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output; [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central effect leading to reduced sympathetic outflow to the periphery; and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin[0m
[31mactivity. Angina Pectoris By blocking catecholamine-induced increases in heart rate, in velocity and extent of myocardial contraction, and in blood pressure, metoprolol reduces the oxygen requirements[0m
[31mof the heart at any given level of effort, thus making it useful in the long-term management of angina pectoris. Myocardial Infarction The precise mechanism of action of metoprolol in patients with [0m
[31msuspected or definite myocardial infarction is not known. METOPROLOL TARTRATE: clinical_pharmacology: Pharmacodynamics Relative beta [0m[1;31m1[0m[31m selectivity is demonstrated by the following: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m In healthy [0m
[31msubjects, metoprolol is unable to reverse the beta [0m[1;31m2[0m[31m -mediated vasodilating effects of epinephrine. This contrasts with the effect of nonselective [0m[1;31m([0m[31mbeta [0m[1;31m1[0m[31m plus beta [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m beta-blockers, which completely[0m
[31mreverse the vasodilating effects of epinephrine. [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m In asthmatic patients, metoprolol reduces FEV [0m[1;31m1[0m[31m and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta [0m[1;31m1[0m[31m [0m
[31m-receptor blocking doses. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at doses much greater than required for beta-blockade. Animal and [0m
[31mhuman experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. METOPROLOL TARTRATE: clinical_pharmacology: Significant beta-blocking effect [0m[1;31m([0m[31mas measured by [0m
[31mreduction of exercise heart rate[0m[1;31m)[0m[31m occurs within [0m[1;31m1[0m[31m hour after oral administration, and its duration is dose-related. For example, a [0m[1;31m50[0m[31m% reduction of the maximum effect after single oral doses of [0m[1;31m20[0m[31m, [0m
[1;31m50[0m[31m, and [0m[1;31m100[0m[31m mg occurred at [0m[1;31m3.3[0m[31m, [0m[1;31m5[0m[31m, and [0m[1;31m6.4[0m[31m hours, respectively, in normal subjects. After repeated oral dosages of [0m[1;31m100[0m[31m mg twice daily, a significant reduction in exercise systolic blood pressure was [0m
[31mevident at [0m[1;31m12[0m[31m hours. When the drug was infused over a [0m[1;31m10[0m[31m-minute period, in normal volunteers, maximum beta-blockade was achieved at approximately [0m[1;31m20[0m[31m minutes. Equivalent maximal beta-blocking effect is[0m
[31machieved with oral and intravenous doses in the ratio of approximately [0m[1;31m2.5[0m[31m:[0m[1;31m1[0m[31m. There is a linear relationship between the log of plasma levels and reduction of exercise heart rate. However, [0m
[31mantihypertensive activity does not appear to be related to plasma levels.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: WARFARIN: clinical_studies_table: [0m[1;31m02[0m[1;31m)[0m[1;31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m22[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.068[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>Recurrent [0m
[31mMI <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m124[0m[31m [0m[1;31m([0m[1;31m6.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m0.66[0m[31m [0m[1;31m([0m[1;31m0.51[0m[31m, [0m[1;31m0.85[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m34[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0[0m[31m. WARFARIN: clinical_studies_table: [0m
[1;31m001[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>Cerebrovascular Event <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m20[0m[31m [0m[1;31m([0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m44[0m[31m [0m[1;31m([0m[1;31m2.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m0.46[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m, [0m[1;31m0.75[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" [0m
[31mToprule"[0m[31m><paragraph>[0m[1;31m54[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0[0m[31m. WARFARIN: clinical_studies_table: [0m[1;31m002[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mcolspan[0m[31m=[0m[31m"5"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>RR = Relative risk; Risk reduction = [0m[1;31m([0m[1;31m1[0m[31m - RR[0m[1;31m)[0m[31m; CI = [0m
[31mConfidence interval; MI = Myocardial infarction; py = patient years <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: TIGECYCLINE: openfda: brand_name         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: generic_name         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: spl_id         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: METOPROLOL TARTRATE: overdosage: OVERDOSAGE Acute Toxicity Several cases of overdosage have been reported, some leading to death. Oral LD [0m[1;31m50[0m[31m â€™s [0m[1;31m([0m[31mmg/kg[0m[1;31m)[0m[31m: mice, [0m[1;31m1158[0m[31m to [0m[1;31m2460[0m[31m; rats, [0m[1;31m3090[0m[31m to [0m
[1;31m4670[0m[31m. Signs and Symptoms Potential signs and symptoms associated with overdosage with metoprolol are bradycardia, hypotension, bronchospasm, myocardial infarction, cardiac failure and death. [0m
[31mManagement There is no specific antidote. In general, patients with acute or recent myocardial infarction may be more hemodynamically unstable than other patients and should be treated accordingly [0m
[1;31m([0m[31msee WARNINGS, Myocardial Infarction [0m[1;31m)[0m[31m. On the basis of the pharmacologic actions of metoprolol, the following general measures should be employed: Elimination of the Drug: Gastric lavage should be [0m
[31mperformed. Other clinical manifestations of overdose should be managed symptomatically based on modern methods of intensive care. METOPROLOL TARTRATE: overdosage: Hypotension: Administer a [0m
[31mvasopressor, e.g., levarterenol or dopamine. Bronchospasm: Administer a beta [0m[1;31m2[0m[31m -stimulating agent and/or a theophylline derivative. Cardiac Failure: Administer digitalis glycoside and diuretic. In [0m
[31mshock resulting from inadequate cardiac contractility, consider administration of dobutamine, isoproterenol or glucagon.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: WARFARIN: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE Warfarin sodium tablets are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism [0m[1;31m([0m[31mPE[0m[1;31m)[0m[31m. [0m
[31mProphylaxis and treatment of thromboembolic complications associated with atrial fibrillation [0m[1;31m([0m[31mAF[0m[1;31m)[0m[31m and/or cardiac valve replacement. Reduction in the risk of death, recurrent myocardial infarction [0m
[1;31m([0m[31mMI[0m[1;31m)[0m[31m, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Limitations of Use Warfarin sodium tablets have no direct effect on an established thrombus, nor [0m
[31mdoes it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary [0m
[31mthromboembolic complications that may result in serious and possibly fatal sequelae. WARFARIN: indications_and_usage: Warfarin sodium tablets are a vitamin K antagonist indicated for: Prophylaxis and [0m
[31mtreatment of venous thrombosis and its extension, pulmonary embolism [0m[1;31m([0m[31m [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve [0m
[31mreplacement [0m[1;31m([0m[31m [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction [0m[1;31m([0m[31m [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Limitations of [0m
[31mUse Warfarin sodium tablets have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: clinical_studies: Major hemorrhages occurred in [0m[1;31m4.6[0m[31m% of patients in the higher intensity INR group compared to zero in the lower intensity INR group. [0m[1;31m14.3[0m[31m Myocardial Infarction [0m
[31mWARIS [0m[1;31m([0m[31mThe Warfarin Re-Infarction Study[0m[1;31m)[0m[31m was a double-blind, randomized study of [0m[1;31m1214[0m[31m patients [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m weeks post-infarction treated with warfarin to a target INR of [0m[1;31m2.8[0m[31m to [0m[1;31m4.8[0m[31m. The primary endpoint [0m
[31mwas a composite of total mortality and recurrent infarction. A secondary endpoint of cerebrovascular events was assessed. Mean follow-up of the patients was [0m[1;31m37[0m[31m months. The results for each endpoint [0m
[31mseparately, including an analysis of vascular death, are provided in Table [0m[1;31m7[0m[31m . WARFARIN: clinical_studies: Table [0m[1;31m7[0m[31m: WARIS â€“ Endpoint Analysis of Separate Events % Risk Warfarin Placebo Reduction Event[0m
[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m [0m[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m RR [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m [0m[1;31m([0m[31m p -value[0m[1;31m)[0m[31m Total Patient Years of Follow-up [0m[1;31m2018[0m[31m [0m[1;31m1944[0m[31m Total Mortality [0m[1;31m94[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m123[0m[31m [0m[1;31m([0m[1;31m6.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.76[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m0.97[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.030[0m[1;31m)[0m[31m Vascular Death [0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m
[1;31m105[0m[31m [0m[1;31m([0m[1;31m5.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.78[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m1.02[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.068[0m[1;31m)[0m[31m Recurrent MI [0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m124[0m[31m [0m[1;31m([0m[1;31m6.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.66[0m[31m [0m[1;31m([0m[1;31m0.51[0m[31m, [0m[1;31m0.85[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0[0m[31m. WARFARIN: clinical_studies: [0m[1;31m001[0m[1;31m)[0m[31m Cerebrovascular Event [0m[1;31m20[0m[31m [0m[1;31m([0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m44[0m[31m [0m
[1;31m([0m[1;31m2.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.46[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m, [0m[1;31m0.75[0m[1;31m)[0m[31m [0m[1;31m54[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.002[0m[1;31m)[0m[31m RR = Relative risk; Risk reduction = [0m[1;31m([0m[1;31m1[0m[31m - RR[0m[1;31m)[0m[31m; CI = Confidence interval; MI = Myocardial infarction; py = patient years WARIS II [0m[1;31m([0m[31mThe Warfarin, Aspirin, [0m
[31mRe-Infarction Study[0m[1;31m)[0m[31m was an open-label, randomized study of [0m[1;31m3630[0m[31m patients hospitalized for acute myocardial infarction treated with warfarin to a target INR [0m[1;31m2.8[0m[31m to [0m[1;31m4.2[0m[31m, aspirin [0m[1;31m160[0m[31m mg per day, or [0m
[31mwarfarin to a target INR [0m[1;31m2[0m[31m to [0m[1;31m2.5[0m[31m plus aspirin [0m[1;31m75[0m[31m mg per day prior to hospital discharge. The primary endpoint was a composite of death, nonfatal reinfarction, or thromboembolic stroke. WARFARIN: [0m
[31mclinical_studies: The mean duration of observation was approximately [0m[1;31m4[0m[31m years. The results for WARIS II are provided in Table [0m[1;31m8[0m[31m . Table [0m[1;31m8[0m[31m: WARIS II â€“ Distribution of Events According to Treatment Group[0m
[31mEvent Aspirin [0m[1;31m([0m[31mN = [0m[1;31m1206[0m[1;31m)[0m[31m Warfarin [0m[1;31m([0m[31mN = [0m[1;31m1216[0m[1;31m)[0m[31m Aspirin plus Warfarin [0m[1;31m([0m[31mN = [0m[1;31m1208[0m[1;31m)[0m[31m Rate Ratio [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m p -value No. of Events Major Bleeding a [0m[1;31m8[0m[31m [0m[1;31m33[0m[31m [0m[1;31m28[0m[31m [0m[1;31m3.35[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m4.00[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Minor Bleeding d [0m[1;31m39[0m[31m [0m[1;31m103[0m[31m [0m
[1;31m133[0m[31m [0m[1;31m3.21[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m2.55[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Composite Endpoints e [0m[1;31m241[0m[31m [0m[1;31m203[0m[31m [0m[1;31m181[0m[31m [0m[1;31m0.81[0m[31m [0m[1;31m([0m[1;31m0.69[0m[31m to [0m[1;31m0.95[0m[1;31m)[0m[31m b [0m[1;31m0.03[0m[31m [0m[1;31m0.71[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m to [0m[1;31m0.83[0m[1;31m)[0m[31m c [0m[1;31m0[0m[31m. WARFARIN: clinical_studies: [0m[1;31m001[0m[31m Reinfarction [0m[1;31m117[0m[31m [0m[1;31m90[0m[31m [0m[1;31m69[0m[31m [0m[1;31m0.56[0m[31m [0m[1;31m([0m[1;31m0.41[0m[31m to [0m[1;31m0.78[0m[1;31m)[0m[31m b < [0m
[1;31m0.001[0m[31m [0m[1;31m0.74[0m[31m [0m[1;31m([0m[1;31m0.55[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m c [0m[1;31m0.03[0m[31m Thromboembolic Stroke [0m[1;31m32[0m[31m [0m[1;31m17[0m[31m [0m[1;31m17[0m[31m [0m[1;31m0.52[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m b [0m[1;31m0.03[0m[31m [0m[1;31m0.52[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.97[0m[1;31m)[0m[31m c [0m[1;31m0.03[0m[31m Death [0m[1;31m92[0m[31m [0m[1;31m96[0m[31m [0m[1;31m95[0m[31m [0m[1;31m0.82[0m[31m a Major bleeding episodes were defined as nonfatal cerebral [0m
[31mhemorrhage or bleeding necessitating surgical intervention or blood transfusion. b The rate ratio is for aspirin plus warfarin as compared with aspirin. c The rate ratio is for warfarin as compared [0m
[31mwith aspirin. d Minor bleeding episodes were defined as non-cerebral hemorrhage not necessitating surgical intervention or blood transfusion.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: TIGECYCLINE: clinical_studies_table: <table [0m[31mID[0m[31m=[0m[31m"t11"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><caption [0m[31mID[0m[31m=[0m[31m"G27e24559[0m[31m-6ed6-49f7-a922-9571f94945ca"[0m[31m>Table [0m[1;31m10[0m[31m. Post-hoc Analysis of Clinical Cure Rates in Patients with [0m
[31mCommunity-Acquired Bacterial Pneumonia Based on Risk of Mortality<sup>a<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mcaption[0m[31m><colgroup><col [0m[31malign[0m[31m=[0m[31m"left"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><[0m[31m/[0m[31mcolgroup[0m[31m><thead><tr><th/><th>Tigecycline for injection<[0m[31m/[0m[31mth[0m[31m><th>Levofloxacin<[0m[31m/[0m[31mth[0m[31m><th/><[0m[31m/[0m[31mtr[0m[31m><tr><th/><th>n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m <[0m[31m/[0m[31mth[0m[31m><th>n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m <[0m[31m/[0m[31mth[0m[31m><th>[0m[1;31m95[0m[31m% [0m
[31mCI<sup>b<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mth[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mthead[0m[31m><tfoot><tr><td [0m[31mcolspan[0m[31m=[0m[31m"4"[0m[31m><sup>a<[0m[31m/[0m[31msup[0m[31m TIGECYCLINE: clinical_studies_table: > Patients at higher risk of death include patients with any one of the following: [0m
[31m&#x2265;[0m[1;31m50[0m[31m year of age; PSI score &#x2265;[0m[1;31m3[0m[31m; or bacteremia due to <content [0m[31mstyleCode[0m[31m=[0m[31m"italics"[0m[31m>Streptococcus pneumoniae<[0m[31m/[0m[31mcontent[0m[31m><paragraph><sup>b<[0m[31m/[0m[31msup[0m[31m> [0m[1;31m95[0m[31m% confidence interval for the treatment [0m
[31mdifference<[0m[31m/[0m[31mparagraph[0m[31m><paragraph><sup>c<[0m[31m/[0m[31msup[0m[31m> After at least [0m[1;31m3[0m[31m days of intravenous therapy, a switch to oral levofloxacin [0m[1;31m([0m[1;31m500[0m[31m mg daily[0m[1;31m)[0m[31m was permitted for both treatment arms in Study [0m[1;31m1[0m[31m. TIGECYCLINE: [0m
[31mclinical_studies_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtfoot[0m[31m><tbody><tr><td>Study [0m[1;31m1[0m[31m<sup>c<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> CE <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m93[0m[31m/[0m[1;31m103[0m[31m [0m[1;31m([0m[1;31m90.3[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m84[0m[31m/[0m[1;31m102[0m[31m [0m[1;31m([0m[1;31m82[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-2.3[0m[31m, [0m[1;31m18.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m32[0m[31m/[0m[1;31m35[0m[31m [0m[1;31m([0m[1;31m91.4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m52[0m[31m/[0m[1;31m54[0m[31m [0m[1;31m([0m[1;31m96.3[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-20.8[0m[31m, [0m[1;31m7[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> c-mITT [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m111[0m[31m/[0m[1;31m142[0m[31m [0m[1;31m([0m[1;31m78.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m100[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m74.6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-6.9[0m[31m, [0m[1;31m14[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m38[0m[31m/[0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m77[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m6[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-22.8[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m7[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td>Study [0m[1;31m2[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> CE <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m95[0m[31m/[0m[1;31m107[0m[31m [0m[1;31m([0m[1;31m88[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m8[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m68[0m[31m/[0m[1;31m85[0m[31m [0m[1;31m([0m[1;31m80[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-2.2[0m[31m, [0m[1;31m20.3[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m33[0m[31m/[0m[1;31m37[0m[31m [0m[1;31m([0m[1;31m89.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m48[0m[31m/[0m[1;31m51[0m[31m [0m[1;31m([0m[1;31m94.1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-21.1[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> c-mITT <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m112[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m83.6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m93[0m[31m/[0m[1;31m120[0m[31m [0m[1;31m([0m[1;31m77.5[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-4.2[0m[31m, [0m[1;31m16.4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m70[0m[31m/[0m[1;31m80[0m[31m [0m[1;31m([0m[1;31m87.5[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-16.2[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: [0m
[31mclinical_studies_table: [0m[1;31m8[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:TIGECYCLINE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The FDA label for TIGECYCLINE does not mention an increased or decreased risk of myocardial infarction.[0m

[32mSOURCE: TIGECYCLINE label[0m
[32mEXTRACT_START_END: TIGECYCLINE: adverse_reactions: [0m[1;32m6[0m[32m ADVERSE[0m[32m...[0m[32m and increased SGPT. [0m[1;32m([0m[1;32m6.1[0m[1;32m)[0m
*[1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The FDA label for TIGECYCLINE does not mention an [0m
[34mincreased or decreased risk of myocardial infarction.[0m

[34mSOURCE: TIGECYCLINE label[0m
[34mEXTRACT_START_END: TIGECYCLINE: adverse_reactions: [0m[1;34m6[0m[34m ADVERSE[0m[34m...[0m[34m and increased SGPT. [0m[1;34m([0m[1;34m6.1[0m[1;34m)[0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if the FDA label for TIGECYCLINE mentions an increased or decreased risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the FDA label for TIGECYCLINE does not mention an increased or decreased risk of myocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does TIGECYCLINE increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if the FDA label for TIGECYCLINE mentions an increased or decreased risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the FDA label for TIGECYCLINE does not mention an increased or decreased risk of myocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does TIGECYCLINE increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if the FDA label for TIGECYCLINE mentions an increased or decreased risk of myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded that the FDA label for TIGECYCLINE does not mention an increased or decreased risk of myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for TIGECYCLINE does not mention an increased or decreased risk of myocardial infarction, so I cannot provide a definitive answer to whether TIGECYCLINE increases or decreases the risk [0m
[32mof myocardial infarction.[0m
